What is Innocoll Holdings?
Founded in 1985, Innocoll Holdings operates as a global specialty pharmaceutical entity focused on the development of innovative, collagen-based medical products. The company distinguishes itself through its proprietary, biocompatible, and biodegradable collagen technology, which is precision-engineered for targeted therapeutic applications. By focusing on late-stage development programs, Innocoll bridges the gap between complex material science and clinical efficacy, aiming to improve patient outcomes through advanced drug delivery mechanisms. Its market position is defined by a long-standing commitment to engineering better medicines, supported by a robust intellectual property portfolio and a deep understanding of collagen-based biomaterials.
How much funding has Innocoll Holdings raised?
Innocoll Holdings has raised a total of $213.5M across 3 funding rounds:
Private Equity
$30M
Stock Offering
$58.5M
Debt
$125M
Private Equity (2007): $30M, investors not publicly disclosed
Stock Issuance/Offering (2014): $58.5M, investors not publicly disclosed
Debt (2022): $125M supported by Oaktree
Key Investors in Innocoll Holdings
Oaktree
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments, recognized for its opportunistic and risk-controlled approach across credit and equity markets.
Undisclosed Investors
Undisclosed Investors
What's next for Innocoll Holdings?
With the recent strategic investment, Innocoll Holdings is well-positioned to accelerate its late-stage clinical trials and navigate the regulatory pathways required for commercialization. The company's forward-looking strategy centers on scaling its manufacturing capabilities and expanding the clinical utility of its collagen platform. By prioritizing high-impact therapeutic areas, Innocoll aims to solidify its market share and deliver long-term value to stakeholders. The focus remains on achieving regulatory milestones that will validate its precision-engineered products, ultimately transforming the standard of care in its targeted medical segments. As the firm moves into this next phase of growth, the integration of its recent capital will be pivotal in sustaining its competitive advantage in the global biotech arena.
See full Innocoll Holdings company page
